Tofacitinib analogues

A compound and pharmaceutical technology, applied in the field of tofacitinib analogs, can solve problems such as inability to apply, adverse reactions, etc., and achieve a significant therapeutic effect

Inactive Publication Date: 2018-03-09
WUXI FORTUNE PHARMA
View PDF8 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still some patients who do not respond

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tofacitinib analogues
  • Tofacitinib analogues
  • Tofacitinib analogues

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] The present invention will be described in detail below in conjunction with various embodiments, but it should be noted that these embodiments are not limitations of the present invention, and those of ordinary skill in the art can make functional, method, or structural equivalent transformations or replacements based on these embodiments. , all fall within the protection scope of the present invention.

[0020] Unless otherwise specified, the term "room temperature" in each embodiment of this specification is specifically 23°C; the term "h" is specifically the unit of time measurement: hour; the term "min" is specifically the unit of time measurement: minute; the term "ml" is specifically the unit of measurement for time: The unit of volume: milliliter; the term "L" specifically refers to the unit of volume: liter; the term "mol / L" specifically refers to the unit of concentration. The term "mmol" is specifically the unit of the amount of a substance, ie millimole; the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides tofacitinib analogues. The analogues contain a compound represented by a formula (I) in the description or a pharmaceutically-acceptable salt of the compound. The invention also discloses a pharmaceutical composition containing the compound represented by the formula I and an application.

Description

technical field [0001] The invention relates to the technical field of pharmacy, in particular to a tofacitinib analogue. Background technique [0002] Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease characterized by joint synovitis and symmetrical and destructive joint lesions. The research on the pathogenesis and treatment of RA has been in continuous development. Many studies have tried to find therapeutic opportunities from different channels such as intracellular signal transduction pathways and cytokines, and have made some progress. For example, methotrexate (MTX) has achieved good results in the treatment of RA since its clinical application in 1980; the first biological agent (TNF inhibitor) targeting tumor necrosis factor (TNF) mainly interferes with T cells, B Cells and other immune cell receptors and inflammatory cytokines) was used in the treatment of RA in 2000, which is a new milestone. Since more and more RA patients are not sensitive ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D519/00A61K31/519A61P37/06A61P29/00A61P19/02
Inventor 王涛王彬彬王庆林孙益林游本加曹娜
Owner WUXI FORTUNE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap